-The Hindu Attempt to commit suicide should stay on the statute book because suicide comes in conflict with the monopolistic power of the state to take away life You choose your country, you choose your spouse, you choose your profession, you choose your political masters, and you choose where you want to live and how. Die you must. But how to die and when: should that be a matter of choice as...

-Economic and Political Weekly   The High-Level Committee set up by the Narendra Modi government to review the major laws relating to environment protection has, in its recommendations, worked towards two sets of objectives: one, to separate business from the messiness of governance, and, two, to redraw the line of demarcation between the judiciary and the executive. Manju Menon (manjumenon@namati.org) and Kanchi Kohli (kanchikohli@namati.org) are with the Centre for Policy Research - Namati...

-PTI A post card campaign will be launched from tommorrow by some city-based activists against the Centre's proposal to make changes in the MNREGA scheme which will affect the poor people. As per the plan, around 1,000 letters will be sent to the PMO everyday till May 1, asking the government not to bring any changes in the scheme. "The NDA government proposed a 15 per cent reduction in the budget allocation...

-Down to Earth National human rights Commission has sought report from the state The K Chandrasekhar Rao government in Telangana seems to have failed to deliver on its promise of reforming the crisis-ridden farm sector in the state. Unofficial figures suggest that more than 400 farmers have committed suicide in the past six months. Telangana, the youngest state in the country, came into existence on June 2 this year. Rao and other leaders...

-The Times of India MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law. Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV,...